Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients
Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a broad population of early breast cancer patients. The UK regulator has approved the drug for use in combination with an aromatase …